R&D Innovation to Lead the Future, Deepening Customer Value Creation From the performance during the 2023 reporting period, GenScript Group's overall development is optimistic, with each business ...

GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been selected as finalists for the Entrepreneur Of The Year(R) 2026 New Jersey Award by Ernst & ...

Advancing Climate Action, Governance Excellence, and Global Scientific ImpactPISCATAWAY, N.J., April 14, 2026 /PRNewswire/ -- GenScript Biotech Corporation today announced its 2025 Environmental ...

GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been selected as ...

PISCATAWAY, N.J., March 12, 2024 /PRNewswire/ -- On March 11, 2024, GenScript Biotech Corporation (HK.1548), a world's leading technology and service provider of life science R&D and manufacturing, ...

SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and GenScript Biotech Corporation ...

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

NANJING, China, Jan. 4, 2024 /PRNewswire/ -- GenScript Biotech, a global leader in life science research and manufacturing services, along with its subsidiaries GenScript ProBio and Legend Biotech, ...

GenScript Biotech Corporation today announced that CEO Sherry Shao and Co-Founder Dr. Frank Zhang have been selected as finalists for the Entrepreneur ...

Jefferies analyst Chris Lui maintained a Buy rating on Genscript Biotech (GNNSF – Research Report) on December 21 and set a price target of HK$30.00. The company’s shares closed last Tuesday at $2.65.

Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its 48% holding ...